Article info

Download PDFPDF

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Authors

  1. a mr7db{at}virginia.edu
  2. b patricia.mccoon{at}astrazeneca.com
  3. c carl.cook{at}astrazeneca.com
  4. d paul.lyne{at}astrazeneca.com
  5. e rkurzrock{at}ucsd.edu
  6. f yokim{at}ionisph.com
  7. g richard.woessner{at}astrazeneca.com
  8. h younesa{at}mskcc.org
  9. i jnemunaitis{at}marycrowley.org
  10. j nfowler{at}mdanderson.org
  11. k mcurran{at}mdanderson.org
  12. l liuqinyingbio{at}163.com
  13. m tzhou{at}ionisph.com
  14. n jschmidt{at}ionisph.com
  15. o mjo{at}ionisph.com
  16. p sjlee{at}ionisph.com
  17. q myamashita{at}ionisph.com
  18. r shughes{at}ionisph.com
  19. s lefayad{at}mdanderson.org
  20. t spihapau{at}mdanderson.org
  21. u murali.nadella{at}astrazeneca.com
  22. v XXiao{at}ionisph.com
  23. w JHsu{at}ionisph.com
  24. x ARevenko{at}ionisph.com
  25. y BMonia{at}ionisph.com
  26. z RMacLeod{at}ionisph.com
  27. { (713) 563-5844 dshong{at}mdanderson.org
View Full Text

Citation

Reilley MJ, McCoon P, Cook C, et al
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Publication history

  • Received July 12, 2018
  • Accepted October 28, 2018
  • First published November 16, 2018.
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.